Journal Pre-proof

A scoping review establishes need for consensus guidance on reporting health equity in observational studies

Xiaoqin Wang, Omar Dewidar, Anita Rizvi, Jimmy Huang, Payaam Desai, Rebecca Doyle, Elizabeth Ghogomu, Tamara Rader, Stuart G. Nicholls, Alba Antequera, Alison Krentel, Beverley Shea, Billie-Jo Hardy, Catherine Chamberlain, Charles S. Wiysonge, Cindy Feng, Clara Juando-Prats, Daeria O. Lawson, Ekwaro A. Obuku, Elizabeth Kristjansson, Erik von Elm, Harry Wang, Holly Ellingwood, Hugh Sharma Waddington, Jacqueline Ramke, Janet Elizabeth Jull, Janet Hatcher-Roberts, Janice Tufte, Julian Little, Lawrence Mbuagbaw, Laura Weeks, Loveline Lum Niba, Luis Gabriel Cuervo, Luke Wolfenden, Mwenya Kasonde, Marc T. Avey, Melissa K. Sharp, Michael Johnson Mahande, Miriam Nkangu, Olivia Magwood, Peter Craig, Peter Tugwell, Sarah Funnell, S.G. Noorduyn, Tamara Kredo, Tanya Horsley, Taryn Young, Tomas Pantoja, Zulfigar Bhutta, Andrea Martel, Vivian A. Welch

PII:S0895-4356(23)00156-7DOI:https://doi.org/10.1016/j.jclinepi.2023.06.009Reference:JCE 11112To appear in:Journal of Clinical EpidemiologyReceived Date:29 December 2022Revised Date:30 April 2023Accepted Date:9 June 2023

Please cite this article as: Wang X, Dewidar O, Rizvi A, Huang J, Desai P, Doyle R, Ghogomu E, Rader T, Nicholls SG, Antequera A, Krentel A, Shea B, Hardy B-J, Chamberlain C, Wiysonge CS, Feng C, Juando-Prats C, Lawson DO, Obuku EA, Kristjansson E, von Elm E, Wang H, Ellingwood H, Waddington HS, Ramke J, Elizabeth Jull J, Hatcher-Roberts J, Tufte J, Little J, Mbuagbaw L, Weeks L, Niba LL, Cuervo LG, Wolfenden L, Kasonde M, Avey MT, Sharp MK, Mahande MJ, Nkangu M, Magwood O, Craig P, Tugwell P, Funnell S, Noorduyn S, Kredo T, Horsley T, Young T, Pantoja T, Bhutta Z, Martel A, Welch VA, A scoping review establishes need for consensus guidance on reporting health equity in observational studies, *Journal of Clinical Epidemiology* (2023), doi: https://doi.org/10.1016/j.jclinepi.2023.06.009.



This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Published by Elsevier Inc.

A scoping review establishes need for consensus guidance on reporting health equity in observational studies

- 3
 4 Xiaoqin Wang 1*, Omar Dewidar 2, Anita Rizvi 3, Jimmy Huang 2, Payaam Desai 2, Rebecca Doyle 2,
- 5 Elizabeth Ghogomu 2, Tamara Rader 4, Stuart G Nicholls 5, Alba Antequera 6, Alison Krentel 2,7,
- 6 Beverley Shea 2,7, Billie-Jo Hardy 8,9, Catherine Chamberlain 10, Charles S. Wiysonge 11-13, Cindy Feng
- 7 14, Clara Juando-Prats 8,9, Daeria O. Lawson 15, Ekwaro A. Obuku 16-18, Elizabeth Kristjansson 3, Erik
- 8 von Elm 19, Harry Wang 2,20, Holly Ellingwood 21, Hugh Sharma Waddington 22,23, Jacqueline Ramke
- 9 24,25, Janet Elizabeth Jull 26, Janet Hatcher-Roberts 2,7, Janice Tufte 27, Julian Little 7, Lawrence
- 10 Mbuagbaw 28-32, Laura Weeks 33, Loveline Lum Niba 34, Luis Gabriel Cuervo 35, Luke Wolfenden 36,
- 11 Mwenya Kasonde 37, Marc T Avey 38, Melissa K. Sharp 39, Michael Johnson Mahande 40, Miriam
- 12 Nkangu 7, Olivia Magwood 2,41, Peter Craig 42, Peter Tugwell 2,7, 43, Sarah Funnell 44,45, SG Noorduyn
- 13 15, Tamara Kredo 12, Tanya Horsley 46, Taryn Young 11, Tomas Pantoja 47, Zulfiqar Bhutta 48,49,
- 14 Andrea Martel 50, Vivian A Welch 2,7
- 15
- Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, ON L8S
 4L8, Canada
- 18 2. Bruyère Research Institute, Ottawa, ON K1R 6M1, Canada
- School of Psychology, University of Ottawa, Faculty of Social Sciences, Ottawa, ON K1N
 6N5, Canada
- 21 4. Freelance health research librarian, (no affiliation), Ottawa, Canada
- 22 5. Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada
- 6. International Health Department. ISGlobal, Hospital Clínic Universitat de Barcelona, 585, 08007
 Barcelona, Spain.
- 25 7. School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1N 6N5, Canada
- 26 8. Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S, Canada
- 27 9. Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, ON M5B 1T8, Canada
- 10. Indigenous Health Equity Unit, Melbourne School of Population and Global Health, The University of
 Melbourne, Parkville VIC 3010, Victoria, Australia
- 30 11. Centre for Evidence-based Health Care, Department of Global Health, Stellenbosch University, Cape
 31 Town 7505, South Africa
- 32 12. Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa
- 13. HIV and other Infectious Diseases Research Unit, South African Medical Research Council, Durban
 4091, South Africa
- 14. Department of Community Health and Epidemiology, Faculty of Medicine, Dalhousie University,
 Halifax, NS B3H 4R2, Canada
- 15. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON
 L8S 4L8, Canada
- 39 16. Africa Centre for Systematic Reviews & Knowledge Translation, College of Health Sciences, Makerere
 40 University, Kampala 7062, Uganda
- 41 17. Department of Global Health Security, Infectious Diseases Institute, College of Health Sciences,
 42 Makerere University, Kampala 7062, Uganda
- 43 18. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine,
 44 University of London, London WC1E 6BT, United Kingdom

- 45 19. Cochrane Switzerland, Unisanté Lausanne, Lausanne CH-1010, Switzerland
- 46 20. University of Ottawa Faculty of Medicine, Ottawa, ON K1N 6N5, Canada
- 47 21. Department of Psychology, Department of Law, Carleton University, Ottawa, ON K1S 5B6, Canada
- 48 22. Environmental Health Group, Department of Disease Control, London School of Hygiene & Tropical
 49 Medicine, London WC1E 7HT, UK
- 50 23. London International Development Centre, London, ON N5V 4T3, Canada
- 51 24. International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London WC1E
 52 7HT, UK
- 53 25. School of Optometry and Vision Science, University of Auckland, Auckland 1010, New Zealand
- 54 26. School of Rehabilitation Therapy, Queen's University, Kingston, ON K7L 3N6, Canada
- 55 27. Cochrane Consumer, Seattle, Washington, United States
- 56 28. Department of Anesthesia, McMaster University, Hamilton, ON L8S 4L8, Canada
- 57 29. Department of Pediatrics, McMaster University, Hamilton, ON L8S 4L8, Canada
- 30. Biostatistics Unit, Father Sean O'Sullivan Research Centre, St Joseph's Healthcare, Hamilton, ON L8N
 4A6, Canada
- 60 31. Centre for Development of Best Practices in Health (CDBPH), Yaoundé Central Hospital, VGC6+C52,
 61 Yaoundé, Cameroon
- 62 32. Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University,
 63 Cape Town 7602, South Africa
- 64 33. CADTH, Ottawa, Ontario, Canada.
- 65 34. Department of Public Health, Faculty of Health Sciences, The University of Bamenda, Bamenda,
 66 Cameroon.
- 67 35. Pan American Health Organization (PAHO/WHO), Washington, DC 20037, United States
- 68 36. School of medicine and Public Health, The University of Newcastle, Callaghan NSW 2308, Australia.
- 69 37. Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
- 70 38. Canadian Council on Animal Care, Ottawa, ON K2P 2R3, Canada
- 39. Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin, D02 YN77,
 Ireland
- 40. Department of Epidemiology & Biostatistics, Kilimanjaro Christian Medical University College,
 Kilimanjaro, M8HH+MQ4, Tanzania
- 41. Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada
- 42. MRC/CSO Social and Public Health Science Unit, University of Glasgow, Glasgow G12 8QQ, UK
- 43. Department of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada
- 44. Department of Family Medicine, Queen's University, Kingston, ON K7L 3N6, Canada
- 45. Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1N 6N5,
 Canada
- 46. Royal College of Physicians and Surgeons of Canada, Ottawa, ON K1S 5N8, Canada
- 82 47. Department of Family Medicine, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile
- 48. Centre for Global Child Health, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
- 49. Institute for Global Health and Development, The Aga Khan University, Karachi 74000, Pakistan
- 85 50. University of Toronto, Toronto, ON M5S, Canada
- 86
- 87
- 88
- 89 *Corresponding author: Xiaoqin Wang. E-mail: <u>wangx431@mcmaster.ca; Tel: +1 3658886870</u>.
- 90 Address: Michael G. DeGroote Institute for Pain Research and Care, McMaster University; 1280
- 91 Main Street West, Hamilton, ON, Canada, L8S 1A8

92 Abstract

93 **Objective**

94 To evaluate the support from the available guidance on reporting of health equity in research for
95 our candidate items and to identify additional items for the STROBE (Strengthening Reporting of
96 Observational studies in Epidemiology)-Equity extension.

97 Study design and setting

We conducted a scoping review by searching Embase, MEDLINE, CINAHL, Cochrane Methodology Register, LILACS, and Caribbean Centre on Health Sciences Information up to January 2022. We also searched reference lists and grey literature for additional resources. We included guidance and assessments (hereafter termed "resources") related to conduct and/or

102 reporting for any type of health research with or about people experiencing health inequity.

103 **Results**

We included thirty-four resources, which supported one or more candidate items or contributed to new items about health equity reporting in observational research. Each candidate item was supported by a median of six (range: 1 - 15) resources. In addition, 12 resources suggested 13 new items, such as "report the background of investigators".

108 Conclusions

Existing resources for reporting health equity in observational studies aligned with our interim checklist of candidate items. We also identified additional items that will be considered in the development of a consensus- and evidence-based guideline for reporting health equity in observational studies.

113 Keywords: health equity; observational studies; reporting guideline; scoping review;
114 STROBE_Equity

115

- **Running title**: Consensus guidance on reporting health equity in observational studies is needed
- 118 Word count: 199

Journal Pre-proof

What is new?

Key findings

 All candidate items proposed to extend STROBE (Strengthening Reporting of Observational studies in Epidemiology) for equity were supported by at least one resource.

We identified 13 additional items related to defining health equity terms; these described the role of racism and discrimination, composition and training of the researcher(s), considering relevant factors in the study methods, and data sharing specific to and across equity factors.

What adds to what is known?

• Through the current resources, we confirmed the support of the interim checklist of items and identified new items for reporting health equity in observational studies. This adds an important tool for observational studies, including those underpinning public health, and health systems and services research.

What is the implication and what should change now?

- Researchers designing observational studies could refer to the items from this review when designing and reporting their studies.
- These items will be used for the consensus process to develop a research reporting guideline on health equity to extend STROBE.

125 **1. Introduction**

126 Health inequities are defined as "differences which are unnecessary and avoidable, unfair and 127 unjust" [1]. Health inequities exist across numerous dimensions such as income, education, 128 geographical setting, age, ethnicity and gender; these factors are well documented in influencing 129 health outcomes [2-4]. These health disparities have persisted despite global efforts to reduce them 130 by organizations such as the World Health Organization (WHO) and United Nations International 131 Children's Emergency Fund (UNICEF) [5-8]. Addressing the health needs of populations 132 experiencing inequities requires conducting research merging scientific standards and their 133 sociocultural contexts.

134

135 Observational studies predominate in health-related research[9] and are well-suited to answer 136 research questions of health inequity such as access, implementation, treatment adherence, and 137 public health interventions[10-12]. We defined observational studies as those relevant to the 138 STROBE reporting guideline, including case-control, cohort and cross-sectional studies[13]. 139 Compared with some randomized controlled trials (RCTs), observational studies have inherently 140 stronger external validity because they provide insight about healthcare delivery to all patients in 141 routine practice, the health impacts of policy and practice interventions, and of potentially harmful 142 exposures, including among those populations at risk of disadvantage due to inequities[14, 143 15]. Evidence suggests that strong observational studies such as discontinuity designs, produce estimates which are statistically identical to RCTs[16]. During the COVID-19 pandemic, 144 145 observational studies highlighted the inequities in the direct and indirect consequences of SARS-146 CoV-2 infection and attempts to control it [17-19], thus playing a critical role in informing public 147 health responses [20-22]. In addition, in cases where conducting a RCT would be unethical, 148 observational studies become the most reliable source of evidence[23].

150 Despite the predominance of observational studies in health research, many such studies do not 151 adequately report information such as clear eligibility criteria, reliability and validity of 152 measurements, and details on data gaps[24-28]. The reporting guideline for observational studies 153 (STROBE, Strengthening Reporting of Observational Studies in Epidemiology) [15] released in 154 2007, has been widely used by journals and authors of observational research [29] and has been 155 cited 29,276 times according to Google Scholar as of November 28, 2022[30]. Nonetheless, the 156 reporting of intervention effects across health equity determinants in observational studies is far 157 from ideal. For example, researchers consistently found a lack of integration and reporting of sex 158 and gender in observational studies[31-33]. This gap may be partly because STROBE lacks items 159 tailored for health equity; for example, in describing equity seeking populations, evaluating 160 outcomes across PROGRESS (i.e., place of residence, race/ethnicity/culture/language, gender/sex, 161 religion, education, socioeconomic status, social capital) factors, appraising applicability. As such, 162 it is necessary to develop, endorse, and implement reporting guidelines to improve the reporting 163 of health equity in observational studies [34-36].

164

In response to this gap, we established a global, multi-disciplinary team that includes academics, policymakers, participants with lived experience, practitioners, advisors and regular peer reviewers to journals, funder, and other knowledge users[37] across a range of disciplines including Indigenous health, knowledge translation, equity, social science, epidemiology, biostatistics, and other health sciences. We aim to develop the STROBE_Equity extension to encourage transparent, concise and comprehensive reporting of health equity in observational studies [38]. As described in a previous study[17], the team formulated an interim checklist of 36 candidate items by

Journal Pre-proo

172 reviewing existing checklists related to equity such as the CONSORT (Consolidated Standards of 173 Reporting Trials)-Equity, the SAGER (Sex and Gender Equity in Research) reporting guidelines 174 and the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)-Equity, 175 and convened a citizen panel (HE, JT, RG) with lived experience of health inequities to seek their 176 feedback. The interim checklist could be found in the **Supplemental Table B1** [17]. 177 178 This scoping review aims to describe the extent to which the available guidance on reporting of 179 health equity in research supports our candidate items (interim guidance) and to identify new items 180 that could be used for the STROBE-Equity extension guideline. 181 182 2. Methods and analysis 183 2.1 Protocol and registration 184 We set up a governance structure of an executive team of four principal investigators (PIs) (VW, 185 LM, JJ, SF) and a lead for each of three steering committees (Indigenous, Knowledge user and 186 Patient/Public) and a Technical Oversight committee to ensure all the team members participated 187 in an integrated knowledge translation process to develop the protocol of this review. The steering

188 committees and Technical Oversight committee are consulted for input on design and delivery of

all the relevant studies under the STROBE_equity project, and for feedback on the research results.

190 The executive team meets monthly with a research coordinator and leaders of the studies to consult 191 on study methods and issues arising during the conduct. The executive team, the Technical

192 Oversight Committee and the steering committees meets quarterly by video conference for project

updating and consultation as needed [39]. Following the JBI method [40], we conducted this study

- in adherence with a peer reviewed protocol published in BMJ Open [41] and reported accordingto the PRISMA reporting guideline for Scoping Reviews[42].
- 196

197 **2.2 Eligibility criteria**

198 We included the following types of resources: 1) guidance related to conduct or reporting for any 199 type of research on, with or about people experiencing health inequity; 2) methodology reviews 200 assessing reporting of equity-related issues of research; 3) summary reports of recommendations 201 on reporting for equity issues in research; and 4) relevant guidance from ethics boards, funders 202 and journal policies on the conduct or reporting of research related to health equity. We excluded 203 resources without recommendation (a statement explaining why specific information is important 204 or recommending reporting specific information in research of health) related to health equity 205 reporting. There was no restriction on language of the publication. As described in the protocol, 206 we decided to conduct two scoping reviews (one for Indigenous and one for 'global' stream) based 207 on the available data and consultation with Indigenous researchers [39, 41]. Here we only included 208 resources that considered non-indigenous populations; resources tailored for research with 209 Indigenous Peoples were designated to the scoping review led by Miranda Lesperance, Sarah 210 Funnell and Andrea Martel to avoid double use. The results of the two scoping reviews will be 211 used together to inform the global and Indigenous STROBE-equity reporting guideline [39]. 212 Indigenous Peoples was defined as "... distinct social and cultural groups that share collective 213 ancestral ties to the lands and natural resources where they live, occupy or from which they have 214 been displaced."[43]

215

Journal Pre-proo

Although there are unique aspects on reporting health equity information in observational studies, we did not restrict the focus to observational studies since guidance for other types of studies, such as randomized clinical trials (RCTs), could also provide important and relevant information that is shared by observational studies. For example, even though the CONSORT equity reporting guideline is focused on RCTs, it has some items that are relevant for observational studies [17, 36].

221

222 **2.3 Search strategy**

223 We searched for both peer and non-peer reviewed published guidance on the reporting and conduct 224 of health equity-related research. The search was conducted in MEDLINE via OVID, LILACS via 225 BIREME-PAHO-WHO Latin American and Caribbean Centre on Health Sciences Information 226 (http://lilacs.bvsalud.org/en/), the Cochrane Methodology Register (Wiley), Embase via OVID, and CINAHL via EbscoHost in January 2022. A full search strategy was developed in MEDLINE 227 228 using the following concepts: (1) health equity (using PROGRESS-Plus [44] characteristics); (2) 229 reporting, analysis and design of research; and (3) guidelines or guidance articles. We assessed 230 relevance of the search results through testing with a set of 11 target articles and modified the 231 search until all these were identified. Searches were limited to records published in 2005 and later 232 considering that: 1) we are interested in recent guidance and conceptualizations of health equity in 233 research; and 2) the establishment of the Commission on Social Determinants of Health by the 234 WHO was in 2005. No language limit or study design limit was applied. Search strategies are 235 presented in Supplementary Table B2. Searches were designed and conducted by a librarian (TR) 236 experienced in systematic reviews, using a method designed to optimize term selection[45]. After 237 identifying eligible full texts from databases, we checked the reference lists for additional eligible 238 studies or documents.

Journal Pre-proot

240 We classified grey literature into five categories and searched for guidance within each: journal 241 guidance from Journal Citation Reports[46], publisher policies from the Joint commitment for 242 action[47], ethics guidance from the International Compilation of Human Research Standards[48], 243 generic research guidance from funding agencies [49], and reporting guidance from interest groups 244 across PROGRESS-Plus factors in consultation with the technical committees. We sampled 245 randomly from these five categories in intervals of 20 documents at a time, stratified by country 246 income setting (i.e., high-income countries (HICs), middle-income countries and low-income 247 countries (LIMCs) as defined by the World Bank to get more representative information from the 248 entire research world (https://data.worldbank.org/country/XD). We decided the information as 249 saturation if no new recommendation was found per category of the grey literature, and we stopped 250 searching further in this case. Detailed methods and results of grey literature are presented in 251 Supplementary Table B3.

252

253 **2.4 Study selection process**

Search results from databases were imported into Covidence (<u>https://www.covidence.org/</u>). Pairs
of reviewers (PD, JH, RD, OD, AR) screened titles and abstracts and full texts in duplicate and
independently. All disagreements were resolved through team discussions.

257

258 **2.5 Data items and extraction**

In this scoping review, we developed the data extraction form based on the interim STROBE_Equity guidance and the 36 candidate items[17] using Microsoft Excel 2022 (Version 16.58). We tested the form three times with 2-3 included resources each time and modified as

Journal Pre-proof

262	required based on feedback from the team. We considered the different publication types and scope
263	of the studies (e.g. we tested our form with reports of different study designs). After three rounds
264	of pilot-testing, we started the formal data abstraction.
265	

Pairs of reviewers (XW, JH, PD, RD, OD, EG) extracted data for each included study
independently and discussed for consensus. A third reviewer (VW) was consulted for a final
decision where necessary. All extractions were verified as an additional data cleaning step (XW).
We collected characteristics on the source, type of organization, scope of the document (e.g.,
population, setting, and type of study design), and methods of development. The extraction form

271 can be found in **Supplementary Appendix A**.

272

For judgments on whether or not the guidance supports the preliminary STROBE_Equity
extension items, we selected from options "support (i.e., suggest reporting)" or "nothing relevant".
We also collected the supporting verbatim text and captured any potential new items as free text
with verbatim quotes from the source document.

277

278

279 **2.6 Methodological quality appraisal**

280 Consistent with the JBI guidance on scoping review conduct, we did not appraise methodological281 quality or risk of bias of the included studies[50].

282

283 **2.7 Data analysis and presentation of the evidence**

Journal Pre-proo

284 We used the principles of framework synthesis to analyse the data[51]. First, we mapped the 285 recommendations to the preliminary STROBE Equity checklist of 36 candidate items as our a 286 priori framework. Online meetings among team members (XW, OD, EG, VW, RD, JH, PD) were 287 held to evaluate the support for each item of the interim checklist and identify any new items. For 288 recommendations that did not match the items in the checklist, we applied an inductive thematic 289 analysis to develop new items or categories as needed[52]. We also assessed the new items for 290 overlapping concepts then combined and drafted wording based on the existing guidance. The wording of the candidate items was then clarified as necessary and finalized with the writing team 291 292 and the wider STROBE_Equity team.

293

Data synthesis included: 1) descriptive quantitative analysis (frequencies and proportions) of the characteristics for included resources and the supporting recommendations for the preliminary STROBE_Equity checklist of candidate items; and 2) qualitative analysis (i.e., content analysis) of supporting recommendations for each candidate or new item.

We presented the results as a map of the extracted data in tabular form based on the *a priori* framework according to the STROBE structure (e.g., introduction, methods, results, discussion). The unit used when counting the number of sources was the study; thus, if a study was published in more than one report, the reports associated with the study were collectively counted as a single source. For example, the GRADE equity guidelines were published as a series of four reports: the first provided a preamble and rationale, and the other three focused on guidance for health guideline developers [53-56].


305

306 **3. Results**

307 3.1 Literature search

308 The electronic database literature search resulted in 12,539 records (Figure 1). We retained 153 309 relevant full-text papers after title and abstract screening. After reviewing the full texts, we found 310 20 eligible studies from academic databases. In addition, we identified seven eligible citations 311 through screening reference lists of included studies and seven eligible resources from the first set 312 of 21 grey literatures. In total, we included 34 eligible resources supporting at least one candidate 313 item or suggested a new item (Supplementary Table B4). Supplementary Table B5 presented 314 the 33 excluded reports that met all the other criteria but did not make recommendations related to 315 reporting health equity.

316



317

320

321

322

323

324

318 **Note** 319 * "W

* "Wrong study type" was applied to any report that did not provide guidance on reporting equity in research (e.g., clinical practice guideline)

** One was the interim Guidelines for Reporting Health Equity in Observational Studies [17], which was part of this STROBE_Equity project; Four studies [57-60] about Indigenous Peoples were separated out for the parallel scoping review led by the Indigenous steering committee.

325 Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow

326 diagram

327

328 Characteristics of included resources that informed any candidate item or new item

Journal Pre-proot

329	Of the 34 included resources, the majority of those informing candidate items were journal articles
330	(n = 24, 71%). Other resources included documents or webpages from research ethics guidance,
331	government, journal editor and non-governmental organizations. The types of resources included
332	varied but were primarily methodology guidelines (11, 32%), reporting guidelines (7, 21%) and
333	research ethics guidance (7, 21%). Of the 17 methodology and reporting guidelines, only five (15%)
334	were developed through consensus. All the resources were published in English and 19 (55%)
335	were published since 2015.

336

Table 1 General characteristics of included resources that informed any reporting items (N=34)

Document publisher	N (%)
Academic journal	24(71)
Research ethics guidance	5(15)
Government	3(9)
Journal editor	1(3)
Non-governmental organization	1(3)
Document type	
Methodology guidelines	11(32)
Reporting guidelines	7(21)
Research ethics guidance	7(21)
Methodology review	5(15)
Editorial/commentary	3(9)
Journal instruction	1(3)
Publication year	
2005-2009	6(18)
2010-2014	9(26)
2015-2019	10(29)
2020-2022	9(26)
Demographic focus	
General population	25(74)
Focused on specific population [*]	9(26)
Clinical area focus	
Non-specific	27(79)

Specific ^{\$}	7(21)
PROGRESS-Plus #	
Gender or Sex	9(26)
Race/ethnicity/culture/language	6(18)
Place of residence	4(12)
Plus: Personal, time-dependent or relationship dependent	1(3)
factors, such as pregnancy, reproductive capacity	
Broad focus [¥]	17(50)
What study design is this document for	
No statement on scope of study design	16(47)
Any type of primary research	7(21)
Clinical trials	4(12)
Any type of evidence synthesis (e.g., systematic review,	4(12)
scoping review)	
Observational studies	2(6)
Clinical practice guidelines	1(3)

^{*}Including transgender health, underserved population, women aged 45–55, people who live in rural and remote area, and resource poor setting.

^{\$} Including oral health, covid 19, psychiatric Anesthesia, women's health, orthopedics, preventative medicine.

[#]Each document could cover more than one factor.

[¥] Broad focus means that the focus is on health equity, but not about specific PROGRESS-Plus factor (e.g., CONSORT-Equity)

345 346

341

342

343

344

347 3.2 Scope of resources that informed any candidate items or new items

348 Of the 34 resources, 9 (26%) focused on specific populations who may experience health inequity,

including transgender individuals [61-63], those in remote/ rural/ underserved/ low-socioeconomic

settings [64-67], women and minorities [68], and women aged 45–55 years [69]; 25 (74%) were

351 focused on health equity with no population restriction. Most (27; 79%) of the resources were non-

352 specific to a certain clinical or public health area, while seven (21%) focused on specific clinical

353 or public health areas, including oral health [70], psychiatry [71], COVID-19[72], anesthesia [73],

orthopedics [74], preventative medicine [75] and gynecology [69]. Half of the resources had no

355 restriction on PROGRESS-Plus factors; another half focused on one or more specific PROGRESS-

356 Plus factors, where 9 (26%) focused on Gender or Sex[62, 63, 68, 69, 73, 74, 76-78], 6 (18%) on

357 Race/ethnicity/culture/language[68-71, 79, 80], 4 (12%) on Place of residence[64-67] and 1 (3%)

on personal, time-dependent or relationship-dependent factors (i.e., menopausal symptoms among
women)[69]. (Table 1)

360

For documents targeting specific study designs, 7 (21%) were for all types of primary research, 4 (12%) for any type of evidence synthesis, 4 (12%) for clinical trials and 2 (6%) for observational studies. (**Table 1**) There were two resources focused on observational studies. One included consolidated criteria for reporting qualitative research (COREQ) including interviews and focus groups[81], and the other was the guidelines for strengthening the reporting of menopause and aging (STROMA) in cross-cultural comparisons study[69].

367

368 **3.3 Supporting recommendations**

369 For the 34 resources informing any candidate item, each resource supported a median of five 370 candidate items (range 1-22). For the 36 candidate items, the median number of resources 371 supporting an item were six (range 1 to 15); all candidate items were supported by at least one 372 resource. Six candidate items (one for rationale, four for methods and one for results) were 373 informed by more than 10 resources and 21 were informed by more than five resources. (Table 2 374 and Supplementary Table B6) Of the candidate items, rationale for focus on health equity in 375 Background (15, 44%), involvement of patients or community experiencing health in equity in 376 Study design (13, 38%), sampling/recruitment methods designed to reach populations across 377 PROGRESS-Plus characteristics in Setting (16, 47%), and details of informed consent and ethical 378 clearance (13, 38%) were the top four items suggested.

379

Journal Pre-proo

380 In addition, 11 resources suggested 13 new items. (Table 2 and Supplementary Table B7). These 381 items included one for *Title* and suggested using a health equity term; two for *Background* on 382 defining health equity terms and describing the role of racism and discrimination; seven applicable 383 to Methods, including topics on reporting the health-equity logic model, composition and training 384 of the researchers considering equity-related factors, reaching people experiencing health inequity, 385 communicating on discontinuation, and describing comparator and technique validation across 386 equity factors; two for *Discussion* on reporting limitations and implications related to health equity; 387 and one for *Data sharing* on reporting the access to raw data across equity.

388

389 4. Discussion

390

We performed a scoping review of available research guidance and relevant documents across
dimensions of health equity from a diverse and comprehensive range of resources to evaluate
support for proposed items for a STROBE_Equity extension.

394

395 Our findings show that existing resources for reporting equity in health research are spread across 396 various document types and formats that may be challenging for authors to access and implement 397 in practice. This review provides a contemporary collation of health equity reporting guidance 398 established from a comprehensive review of literature and serves as an important resource for the 399 field.

400

401 All candidate items were supported by at least one resource with more than half being supported 402 by more than five resources; suggesting a good alignment of our proposed framework with the

Journal Pre-proo

403 current health research landscape. Of these candidate items, rationale for focus on health equity in 404 *Background*, involvement of patients or community experiencing health inequity in *Study design*, 405 sampling/recruitment methods designed to reach populations across PROGRESS-Plus 406 characteristics in Setting, and details of informed consent and ethical clearance were the top four 407 items suggested in the resources we included. Additionally, the 13 new items provided more 408 important information on novel intersections, such as describing the role of racism and 409 discrimination in the experience of health inequity in relation to the problem or intervention, 410 reporting the background and research area of the team members considering relevant experience, and providing information on accessing raw data across equity factors. With all these items 411 412 suggested, our review provides a comprehensive, evidence-based set of reporting items covering 413 all dimensions of reporting health equity in observational studies, including title, abstract, 414 background, methods, result, discussion and other information (e.g. data sharing).

415

416 We identified two resources designed for observational studies, one for qualitative research 417 including interviews and focus groups[81], the other for guidelines for strengthening the reporting 418 of menopause and aging (STROMA) in cross-cultural comparisons study [69]. Neither of these 419 covers the breadth of reporting of health equity in observational studies from design to 420 interpretation. Further, we did not identify any reporting guidance that covers all important aspects 421 of reporting health equity related information in observational studies. Instead, the research guidance related to health equity was fragmented -- existing resources for reporting equity in 422 423 research are spread across various document types and formats that may be challenging for authors 424 to access and implement in practice. Such findings underscore the need for comprehensive 425 reporting resource drawing on such guidance.

427 Including equity reporting guidance for other study designs gave us a broad view of potential 428 important items. Compared to CONSORT-Equity[36] for clinical trials and PRISMA-Equity[35] 429 for systematic reviews, some of our proposes items are shared across different study designs, such 430 as reporting rationale for focus on health equity, sampling methods designed to reach populations 431 across relevant PROGRESS items, and discussing external validity to populations across relevant 432 PROGRESS-Plus characteristics. Some, however, are unique to observational studies, such as 433 "whether the comparator is considered more advantaged or to have less barriers to health 434 opportunities". Further, some items are not covered by CONSORT-Equity and PRISMA-Equity, 435 but may also be relevant for those study designs, such as report the research area (e.g. personnel 436 with unique professional and cultural backgrounds on equity related issues) and social location 437 (i.e., gender, race, etc.) of investigators, describe any process to ensure that the research is reaching 438 the people experiencing health inequity, and report the definitions of health equity related terms. 439

This review, along with other studies that are part of the larger STROBE Equity project, will be used to inform the development of the Equity extension to the STROBE reporting guideline. We will present and discuss the results with technical committees and circulate the checklist using a global online survey, together with findings from a methodological survey of observational studies [13]. These studies and surveys will be used to reach consensus on a STROBE_Equity extension. The protocol for the overall project is available on Open Science Framework[38].

446

447 **Strengths and limitations**

Journal Pre-proo

448 We used the JBI scoping review methodology [50] to map resources on health equity reporting in 449 research from multiple information sources in an attempt to capture guidance produced and used 450 by relevant stakeholders, including from academic journals, journal policies, research ethics 451 boards, publishers, research funding agencies and interest groups. Another strength is that we used 452 multidisciplinary team and multiple knowledge users with defined roles and governance strategy 453 to engage diverse perspectives in designing and study, and analyzing and interpreting the results 454 [41]. One limitation of our approach is that we were not able to review all available guidance from all sources in every setting. Instead, we employed the principle of saturation such that no new 455 456 items were identified. We also used a structured approach by seeking different sources and 457 balancing between sources (i.e. HICs and LMICs) as well as across PROGRESS-Plus 458 characteristics[82]. This helped to identify evidence for all PROGRESS-Plus elements and from 459 different countries or settings. Another limitation is that the checklist is currently draft for 460 consultation, and some of the items need further elaboration, which are expected to be completed 461 as a justification document for the checklist after consensus and global survey [39]. Two examples 462 will be: 1) the item on reporting a contextual factor used in adjustment needs elaboration on that 463 the adjustment may hide important differences that could inform health policy [83] and authors 464 should transparently report on this if conducted; 2) for effort to avoid selection bias, further 465 elaboration could be used to describe whether selection bias is related to outcomes as particular 466 outcomes may be affected by systemic discrimination.

As expected, the included resources varied across publication type, publisher, scope, levels of detail and format, which posed a challenge for comprehensive and consistent data extraction. To ensure accuracy of the data extraction, we did all the data extraction in duplicate, with at least one reviewer experienced in equity research for more than 3 years. Each pair of reviewers discussed

OU1		D	r	n r	\mathbf{O}
Ծա					U.

the results periodically and any questions were presented and solved in weekly team meetings.
Furthermore, a senior reviewer verified every supporting recommendation for each item and all
the results presented were based on agreement among the review authors.

474

475 **5.** Conclusions

476 Existing resources for reporting health equity in research are fragmented and only two included 477 resources were focused on any PROGRESS-Plus factors in observational studies. However, we 478 found a strong agreement of the candidate items of our draft checklist with the current research on 479 reporting of health equity. Based on this review, we have supplemented the checklist with an 480 additional 13 items related to use and define health equity terms, describe the role of racism and 481 discrimination, report background and experience of team members, provide information on logic 482 model, describe process used to reach people experiencing health inequity, describe quality of the 483 comparator (e.g. more advantaged or not), describe the validation of measurements across patients 484 with different backgrounds, report limitations and implications relevant to health equity, and state 485 way to access raw data across PROGRESS-plus factors. This comprehensive, evidence-based set 486 of reporting items will inform the development of the STROBE Equity extension.

487

Contributors: XW, OD, AR, LM, and VW conceptualised this review. TR conducted the
literature search. XW, OD, MM, AR, JH, PD, RJD, and EG screened the references and extracted
the data. XW analyzed the data and drafted the manuscript. OD, AR, EG, TR, SGN, AA, BS, BJH,
CC, CSW, CF, DOL, EAO, EK, EE, HW, HE, CJP, HSW, JR, JGR, JJ, JT, JL, LM, LW, LLN,
LGC, LW, MK, MTA, MKS, MJM, MN, OM, PC, PT, SF, SGN, TK, TH, TY, TP, ZB, AM and
VW revised the manuscript. All authors reviewed and edited the manuscript and approved the final

Journal Pre-proot

draft. The corresponding author attests that all listed authors meet authorship criteria and that noothers meeting the criteria have been omitted.

496 Acknowledgments: The authors acknowledge their partners and collaborators on the STROBE-

497 Equity team: George Wells (Canada), Kevin Pottie (Canada), Isabel Fortier (Canada), Elie A. Akl

498 (Lebanon), Alassane Dicko (Canada), Damian Francis (USA), Regina Greer-Smith (USA),

499 Michelle Kennedy (Australia), Laurenz Langer (South Africa), G.J. Melendez-Torres (UK), David

500 Moher (Canada), Patrick M. Okwen (Cameroon), Jennifer Petkovic (Canada), Mark Petticrew

501 (UK), Alison Riddle (Canada), Larissa Shamseer (Canada), Peter Tanuseputro (Canada), Elizabeth

502 Loder (USA), Howard White (UK), Lucy Barker (Canada), Matire Harwood (New Zealand),

503 Ebenezer Owusu-Addo (Ghana).

504

505 **Competing interests:** While Luis Gabriel Cuervo is an official of the Pan American Health 506 Organization, the views expressed in this publication are his sole responsibility and do not 507 necessarily represent the decisions or policies of the Pan American Health Organization 508 (PAHO/WHO).

509

Funding: This work was supported by the Canadian Institutes of Health Research (CIHR),
grant number 173269. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.

513

514 **References**

515

- 5161.Whitehead M: The concepts and principles of equity and health. Health promotion517international 1991, 6(3):217-228.
- Baciu A, Negussie Y, Geller A, Weinstein JN, National Academies of Sciences E, Medicine: The state of health disparities in the United States. In: *Communities in action: Pathways to health equity*. edn.: National Academies Press (US); 2017.

521 522	3.	Allin S: Does Equity in Healthcare Use Vary across Canadian Provinces? <i>Healthc Policy</i> 2008, 3 (4):83-99.
523	4.	Wang Z, Yang G, Guo Y: Harnessing the opportunity to achieve health equity in
523 524	4.	China . The Lancet Public Health 2021, 6 (12):e867-e868.
525	5.	Solar O, Irwin A. Towards a conceptual framework for analysis and action on the
526		social determinants of health. WHO, Commission on Social Determinants of Health,
527		2007.
528	6.	Marmot M, Friel S, Bell R, Houweling TA, Taylor S, Health CoSDo: Closing the gap in
529		a generation: health equity through action on the social determinants of health. The
530		lancet 2008, 372 (9650):1661-1669.
531	7.	Braveman PA, Kumanyika S, Fielding J, LaVeist T, Borrell LN, Manderscheid R,
532		Troutman A: Health disparities and health equity: the issue is justice. American
533		journal of public health 2011, 101 (S1):S149-S155.
534	8.	Braveman P, Tarimo E: Social inequalities in health within countries: not only an
535		issue for affluent nations. Social science & medicine 2002, 54(11):1621-1635.
536	9.	Funai EF, Rosenbush EJ, Lee M-J, Del Priore G: Distribution of study designs in four
537		major US journals of obstetrics and gynecology. Gynecologic and obstetric
538		investigation 2001, 51 (1):8-11.
539	10.	Petticrew M, Roberts H: Evidence, hierarchies, and typologies: horses for courses.
540		Journal of Epidemiology & Community Health 2003, 57(7):527-529.
541	11.	Tugwell P, Petticrew M, Kristjansson E, Welch V, Ueffing E, Waters E, Bonnefoy J,
542		Morgan A, Doohan E, Kelly MP: Assessing equity in systematic reviews: realising the
543		recommendations of the Commission on Social Determinants of Health. Bmj 2010,
544		341.
545	12.	Craig P, Campbell M, Bauman A, Deidda M, Dundas R, Fitzgerald N, Green J,
546		Katikireddi SV, Lewsey J, Ogilvie D et al: Making better use of natural experimental
547		evaluation in population health. Bmj 2022, 379:e070872.
548	13.	Dewidar O, Rader T, Waddington H et al. Reporting of health equity considerations
549		in equity-relevant observational studies: Protocol for a systematic assessment
550		[version 1; peer review: awaiting peer review]. F1000Research 2022, 11:615
551		(https://doi.org/10.12688/f1000research.122185.1).
552	14.	Booth C, Tannock I: Randomised controlled trials and population-based
553		observational research: partners in the evolution of medical evidence. British journal
554		<i>of cancer</i> 2014, 110 (3):551-555.
555	15.	Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP,
556		Initiative S: The Strengthening the Reporting of Observational Studies in
557		Epidemiology (STROBE) statement: guidelines for reporting observational studies.
558		Annals of internal medicine 2007, 147 (8):573-577.
559	16.	Waddington HS, Villar PF, Valentine JC: Can Non-Randomised Studies of
560		Interventions Provide Unbiased Effect Estimates? A Systematic Review of Internal
561		Replication Studies . <i>Eval Rev</i> 2022:193841x221116721.
562	17.	Antequera A, Lawson DO, Noorduyn SG, Dewidar O, Avey M, Bhutta ZA, Chamberlain
563		C, Ellingwood H, Francis D, Funnell S: Improving social justice in covid-19 health
564		research: Interim guidelines for reporting health equity in observational studies.
565		<i>International journal of environmental research and public health</i> 2021, 18 (17):9357.

566	18.	Paremoer L, Nandi S, Serag H, Baum F: Covid-19 pandemic and the social
567		determinants of health. BMJ 2021, 372:n129.
568	19.	Upshaw TL, Brown C, Smith R, Perri M, Ziegler C, Pinto AD: Social determinants of
569		COVID-19 incidence and outcomes: a rapid review . <i>PloS one</i> 2021, 16 (3):e0248336.
570	20.	Guidance for implementing non pharmacological public health measures in
571		populations in situations of vulnerability in the context of COVID-19. Pan American
572		Health Organization;2020.].
573	21.	Glover RE, van Schalkwyk MC, Akl EA, Kristjannson E, Lotfi T, Petkovic J, Petticrew
574		MP, Pottie K, Tugwell P, Welch V: A framework for identifying and mitigating the
575		equity harms of COVID-19 policy interventions. Journal of clinical epidemiology
576		2020, 128 :35-48.
577	22.	Tenforde MW, Fisher KA, Patel MM: Identifying COVID-19 risk through
578		observational studies to inform control measures. JAMA 2021, 325(14):1464-1465.
579	23.	Faraoni D, Schaefer ST: Randomized controlled trials vs. observational studies: why
580		not just live together? BMC Anesthesiol 2016, 16(1):102.
581	24.	Zachariah R, Rust S, Thekkur P, Khogali M, Kumar AM, Davtyan K, Diro E,
582		Satyanarayana S, Denisiuk O, Griensven JV <i>et al</i> : Quality, Equity and Utility of
583		Observational Studies during 10 Years of Implementing the Structured Operational
584		Research and Training Initiative in 72 Countries . <i>Trop Med Infect Dis</i> 2020, 5 (4).
585	25.	Pocock SJ, Collier TJ, Dandreo KJ, de Stavola BL, Goldman MB, Kalish LA, Kasten LE,
586		McCormack VA: Issues in the reporting of epidemiological studies: a survey of
587		recent practice. BmJ 2004, 329 (7471):883.
588	26.	Tooth L, Ware R, Bain C, Purdie DM, Dobson A: Quality of reporting of observational
589		longitudinal research. American journal of epidemiology 2005, 161(3):280-288.
590	27.	Ziemann S, Paetzolt I, Grüßer L, Coburn M, Rossaint R, Kowark A: Poor reporting
591		quality of observational clinical studies comparing treatments of COVID-19 - a
592		retrospective cross-sectional study. BMC Med Res Methodol 2022, 22(1):23.
593	28.	Quinn TJ, Burton JK, Carter B, Cooper N, Dwan K, Field R, Freeman SC, Geue C, Hsieh
594		PH, McGill K et al: Following the science? Comparison of methodological and
595		reporting quality of covid-19 and other research from the first wave of the
596		pandemic. <i>BMC Med</i> 2021, 19 (1):46.
597	29.	Sharp MK, Bertizzolo L, Rius R, Wager E, Gómez G, Hren D: Using the STROBE
598		statement: survey findings emphasized the role of journals in enforcing reporting
599		guidelines. Journal of clinical epidemiology 2019, 116:26-35.
600	30.	STROBE statement.
601		https://scholar.google.ca/scholar?hl=en&as_sdt=0%2C5&q=+STROBE+statement
602		&oq=strobe. Accessed on November 28, 2022.
603	31.	Dewidar O, Podinic I, Barbeau V, Patel D, Antequera A, Birnie D, Welch V, Wells GA:
604		Integrating sex and gender in studies of cardiac resynchronization therapy: a
605		systematic review. ESC heart failure 2022, 9(1):420-427.
606	32.	Park H, Dewidar O, Tanjong-Ghogomu E, Welch V: Reporting and analysis of Sex and
607		Gender in Transitions of Care for Older Adults: A Methods Study. University of
608		Ottawa Journal of Medicine 2022, 11 (2).
609	33.	Jahn I, Börnhorst C, Günther F, Brand T: Examples of sex/gender sensitivity in
610		epidemiological research: results of an evaluation of original articles published in
611		JECH 2006–2014 . <i>Health research policy and systems</i> 2017, 15 (1):1-10.

612	34.	Schwab S, Janiaud P, Dayan M, Amrhein V, Panczak R, Palagi PM, Hemkens LG,
613		Ramon M, Rothen N, Senn S <i>et al</i> : Ten simple rules for good research practice . <i>PLoS</i>
614	25	<i>Comput Biol</i> 2022, 18 (6):e1010139.
615	35.	Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H: PRISMA -
616		Equity 2012 extension: reporting guidelines for systematic reviews with a focus on
617	2.5	health equity. <i>PLoS Med</i> 2012, 9 (10):e1001333.
618	36.	Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P: CONSORT-
619		Equity 2017 extension and elaboration for better reporting of health equity in
620		randomised trials. <i>Bmj</i> 2017, 359 :j5085.
621	37.	CIHR: Knowledge User Engagement. Available at: https://cihr-
622	•	irsc.gc.ca/e/49505.html. Accessed on December 9, 2022.
623	38.	STROBE-equity reporting guidelines https://osf.io/h57se/.
624	39.	Funnell S, Jull J, Mbuagbaw L, Welch V, Dewidar O, Wang X, Lesperance M, Ghogomu
625		E, Rizvi A, Akl EA et al: Improving social justice in observational studies: protocol
626		for the development of a global and Indigenous STROBE-equity reporting
627		guideline. Int J Equity Health 2023, 22(1):55.
628	40.	Aromataris E, Munn Z, eds. Chapter 11: Scoping reviews. In: JBI Manual for
629		Evidence Synthesis, 2020.
630		https://wiki.jbi.global/display/MANUAL/Chapter+11%3A+Scoping+reviews.
631	41.	Rizvi A, Lawson DO, Young T, Dewidar O, Nicholls S, Akl EA, Little J, Magwood O,
632		Shamseer L, Ghogomu E: Guidance relevant to the reporting of health equity in
633		observational research: a scoping review protocol. BMJ open 2022, 12(5):e056875.
634	42.	Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters
635		MDJ, Horsley T, Weeks L et al: PRISMA Extension for Scoping Reviews (PRISMA-
636		ScR): Checklist and Explanation. Ann Intern Med 2018, 169(7):467-473.
637	43.	Bank TW. Indigenous Peoples Overview: The World Bank; 2022. Available from:
638		https:// www. world bank. org/ en/ topic/ indig enous peopl es.
639	44.	O'Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, Evans T, Pardo Pardo J,
640		Waters E, White H et al: Applying an equity lens to interventions: using PROGRESS
641		ensures consideration of socially stratifying factors to illuminate inequities in health
642		J Clin Epidemiol 2014, 67(1):56-64.
643	45.	Bramer WM, de Jonge GB, Rethlefsen ML, Mast F, Kleijnen J: A systematic approach
644		to searching: an efficient and complete method to develop literature searches. J Med
645		<i>Libr Assoc</i> 2018, 106 (4):531-541.
646	46.	https://jcr.clarivate.com/jcr/browse-journals.
647	47.	https://www.rsc.org/new-perspectives/talent/joint-commitment-for-action-inclusion-
648		and-diversity-in-publishing/.
649	48.	https://www.hhs.gov/ohrp/sites/default/files/2020-international-compilation-of-
650		human-research-standards.pdf.
651	49.	Viergever RF, Hendriks TC: The 10 largest public and philanthropic funders of
652		health research in the world: what they fund and how they distribute their funds.
653		Health Res Policy Syst 2016, 14:12.
654	50.	Peters MD, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H: Chapter 11:
655		scoping reviews (2020 version). JBI manual for evidence synthesis, JBI 2020, 2020.

656	51.	Carroll C, Booth A, Cooper K: A worked example of" best fit" framework synthesis:
657		a systematic review of views concerning the taking of some potential
658		chemopreventive agents . <i>BMC medical research methodology</i> 2011, 11 (1):1-9.
659	52.	Miles MB, Huberman AM, Saldaña J: Qualitative data analysis: A methods
660		sourcebook: Sage publications; 2018.
661	53.	Welch VA, Akl EA, Guyatt G, Pottie K, Eslava-Schmalbach J, Ansari MT, de Beer H,
662		Briel M, Dans T, Dans I et al: GRADE equity guidelines 1: considering health equity
663		in GRADE guideline development: introduction and rationale. J Clin Epidemiol
664		2017, 90 :59-67.
665	54.	Akl EA, Welch V, Pottie K, Eslava-Schmalbach J, Darzi A, Sola I, Katikireddi SV, Singh
666		J, Murad MH, Meerpohl J et al: GRADE equity guidelines 2: considering health
667		equity in GRADE guideline development: equity extension of the guideline
668		development checklist.68-75.
669	55.	Welch VA, Akl EA, Pottie K, Ansari MT, Briel M, Christensen R, Dans A, Dans L,
670		Eslava-Schmalbach J, Guyatt G et al: GRADE equity guidelines 3: considering health
671		equity in GRADE guideline development: rating the certainty of synthesized
672		evidence.76-83.
673	56.	Pottie K, Welch V, Morton R, Akl EA, Eslava-Schmalbach JH, Katikireddi V, Singh J,
674		Moja L, Lang E, Magrini N et al: GRADE equity guidelines 4: considering health
675		equity in GRADE guideline development: evidence to decision process. J Clin
676		<i>Epidemiol</i> 2017, 90 :84-91.
677	57.	Pyett P, Waples-Crowe P, van der Sterren A: Engaging with Aboriginal communities
678		in an urban context: some practical suggestions for public health researchers. Aust N
679		<i>Z J Public Health</i> 2009, 33 (1):51-54.
680	58.	Azzopardi P, Blow N, Purcell T, Brown N, Ritchie T, Brown A: Investing in the health
681		of Aboriginal and Torres Strait Islander adolescents: a foundation for achieving
682		health equity. Med J Aust 2020, 212(5):202-204.e201.
683	59.	Huria T, Palmer SC, Pitama S, Beckert L, Lacey C, Ewen S, Smith LT: Consolidated
684		criteria for strengthening reporting of health research involving indigenous peoples:
685		the CONSIDER statement. BMC Med Res Methodol 2019, 19(1):173.
686	60.	Bartlett JG, Iwasaki Y, Gottlieb B, Hall D, Mannell R: Framework for Aboriginal-
687		guided decolonizing research involving Métis and First Nations persons with
688		diabetes. Soc Sci Med 2007, 65(11):2371-2382.
689	61.	Tordoff DM, Minalga B, Gross BB, Martin A, Caracciolo B, Barbee LA, Balkus JE,
690		Khosropour CM: Erasure and Health Equity Implications of Using Binary
691		Male/Female Categories in Sexual Health Research and Human Immunodeficiency
692		Virus/Sexually Transmitted Infection Surveillance: Recommendations for
693		Transgender-Inclusive Data Collection and Reporting. Sex Transm Dis 2022,
694		49 (2):e45-e49.
695	62.	Adams N, Pearce R, Veale J, Radix A, Castro D, Sarkar A, Thom KC: Guidance and
696		Ethical Considerations for Undertaking Transgender Health Research and
697		Institutional Review Boards Adjudicating this Research. Transgend Health 2017,
698		2 (1):165-175.
699	63.	CPATH Ethical Guidelines for Research Involving
700	Trans	gender People & Communities. Accessed at: https://cpath.ca/wp-
701		content/uploads/2019/08/CPATH-Ethical-Guidelines-EN.pdf. (2020/08/08).

702	64.	Matsuda Y, Brooks JL, Beeber LS: Guidelines for research recruitment of
703		underserved populations (EERC). Appl Nurs Res 2016, 32:164-170.
704	65.	Matsumoto M, Bowman R, Worley P: A guide to reporting studies in rural and
705		remote health. Rural Remote Health 2012, 12:2312.
706	66.	Robinson A, Burley M, McGrail MR, Drysdale M, Jones R, Rickard CM: The
707		conducting and reporting of rural health research: rurality and rural population
708		issues. Rural Remote Health 2005, 5(4):427.
709	67.	GLOBAL CODE OF CONDUCT FOR RESEARCH IN RESOURCE-POOR
710		SETTINGS . Accessed at: https://www.globalcodeofconductorg/ 2022/08/08.
711	68.	National Institutes of Health. Amendment: NIH policy and guidelines on the
712		inclusion of women and minorities as subjects in clinical research. 2017. Available
713		from: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-014.html
714		[Accessed 08 August 2022].
715	69.	Melby MK, Sievert LL, Anderson D, Obermeyer CM: Overview of methods used in
716	•••	cross-cultural comparisons of menopausal symptoms and their determinants:
717		Guidelines for Strengthening the Reporting of Menopause and Aging (STROMA)
718		studies. Maturitas 2011, 70(2):99-109.
719	70.	Bastos JL, Constante HM, Celeste RK, Haag DG, Jamieson LM: Advancing racial
720	70.	equity in oral health (research): more of the same is not enough. Eur J Oral Sci 2020,
721		128 (6):459-466.
722	71.	Lewis-Fernandez R, Raggio GA, Gorritz M, Duan N, Marcus S, Cabassa LJ, Humensky
723	/1.	J, Becker AE, Alarcon RD, Oquendo MA <i>et al</i> : GAP-REACH: a checklist to assess
724		comprehensive reporting of race, ethnicity, and culture in psychiatric
725		publications.860-871.
726	72.	Witham MD, Anderson E, Carroll CB, Dark PM, Down K, Hall AS, Knee J, Maher ER,
727	12.	Maier RH, Mountain GA <i>et al</i> : Ensuring that COVID-19 research is inclusive:
728		guidance from the NIHR INCLUDE project. <i>BMJ Open</i> 2020, 10 (11):e043634.
728	73.	
	75.	Leslie K, Kasza J: Sex and gender inclusion, analysis, and reporting in anaesthesia
730	74	research.e43-e49.
731	74.	Leopold SS, Beadling L, Dobbs MB, Gebhardt MC, Lotke PA, Manner PA, Rimnac CM,
732		Wongworawat MD: Fairness to all: gender and sex in scientific reporting. <i>Clin</i>
733	75	Orthop Relat Res 2014, 472 (2):391-392.
734	75.	American Journal of Preventive Medicine: Author Instructions. Accessed at:
735		https://wwwelseviercom/journals/american-journal-of-preventive-medicine/0749-
736		3797/guide-for-authors 2022/08/08.
737	76.	Heidari S, Babor TF, De Castro P, Tort S, Curno M: Sex and Gender Equity in
738		Research: rationale for the SAGER guidelines and recommended use.2.
739	77.	Tordoff DM, Minalga B, Gross BB, Martin A, Caracciolo B, Barbee LA, Balkus JE,
740		Khosropour CM: Erasure and health equity implications of using binary male/female
741		categories in sexual health research and HIV/STI surveillance: recommendations
742		for transgender-inclusive data collection and reporting.16.
743	78.	Institute of Medicine Board on Population H, Public Health P: The National Academies
744		Collection: Reports funded by National Institutes of Health. In: Sex-Specific
745		Reporting of Scientific Research: A Workshop Summary. edn. Washington (DC):
746		National Academies Press (US)
747	Copyri	ight © 2012, National Academy of Sciences.; 2012.

748 79. Mir G, Salway S, Kai J, Karlsen S, Bhopal R, Ellison GT, Sheikh A: Principles for 749 research on ethnicity and health: the Leeds Consensus Statement.504-510. 750 Burlew AK, Peteet BJ, McCuistian C, Miller-Roenigk BD: Best practices for 80. 751 researching diverse groups.354-368. 752 Tong A, Sainsbury P, Craig J: Consolidated criteria for reporting qualitative research 81. 753 (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health 754 *Care* 2007, **19**(6):349-357. 755 https://methods.cochrane.org/equity/projects/evidence-equity/progress-plus. 82. 756 Kaufman JS: Statistics, Adjusted Statistics, and Maladjusted Statistics. Am J Law 83. 757 Med 2017, 43(2-3):193-208. 758

Journal Provide States of the second se

Торіс	STROBE checklist	Proposed Item for an Equity Focused Extension in Observational Studies	N (%) of resources
Title and abstract			
Title	1a Indicate the study's design with a commonly used term in the title or the abstract	• If health equity is a major focus, consider using "health equity" or relevant terms in the title. ^{\$#}	2 (6)
Abstract	1b Provide in the abstract an informative and balanced summary of what was done and what was found	 Describe population according to PROGRESS-Plus Describe extent/limits of applicability to populations of interest across PROGRESS-Plus characteristics 	8 (24) 6 (18)
Background/rationa	ale		
	2 Explain the scientific background and rationale for the investigation being	equity? #	15 (44)
	reported	 Describing role of racism, discrimination and exclusion in health inequities across one or more PROGRESS-plus factors in relationship to the research questions. ^{\$#} 	1 (3)
	None	• Report the definitions of health equity related terms. ^{\$#}	1 (3)
Objectives	3. State specific objectives, including any pre specified hypotheses		
Method			
Study design	4 Present key elements of study design early in the paper	• Report who was involved/engaged/consulted with experience in health equity/inequity in study design (e.g. patients, community, industry, government, etc.) [#]	13 (38)
		• Report the background and research area (e.g. personnel with unique professional and cultural backgrounds on equity related issue) and social location (i.e., gender, race, etc.) of investigators. ^{\$}	4 (12)
		• If applicable, describe whether research staff were selected for or trained with particular skills and experience on working with groups experiencing health inequity (e.g., age inclusion training, disability inclusion training)? ^{\$#}	2 (6)
		• Report whether a theory of change related to equity was described for the study to design analysis #	1 (3)
		• If applicable, provide the information or link to the logic model developed which shows how equity is important ^{\$#}	1 (3)

Table 2 Number of sources identified supporting each of the 36 candidate items and 13 new items.

Setting	5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data	•	Report whether methods of sampling/recruitment were designed to reach populations across relevant PROGRESS- Plus characteristics	16 (47)
	collection	•	Is there possibility of self-selection bias across PROGRESS- Plus factors?	2 (6)
		•	If applicable, describe any process in place to monitor and ensure that the research is reaching the people experiencing health inequity appropriately. ^{§#}	1 (3)
		•	If applicable, describe how pauses or discontinuation across equity factors were managed as well as how to communicate with participants. ^{§#}	1 (3)
Participants	6a. Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	•	Give inclusion and exclusion criteria across relevant PROGRESS-Plus characteristics	9 (26)
	Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	R	Report context and relationship to health equity. #	8 (24)
	Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants	•	Report details of partnerships with populations and communities, where applicable. [#]	11 (32)
	6b. Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case	•	Report whether any PROGRESS-Plus factors used for matching, how categories were determined and why	1 (3)
	None	•	If applicable, describe whether the comparator is considered more advantaged or to have less barriers to health opportunities. ^{\$#}	1 (3)
Variable	7 Clearly define all outcomes, exposures, predictors, potential confounders, and	•	Report whether outcomes were identified as relevant and important to populations across PROGRESS-Plus	10 (29)
	effect modifiers. Give diagnostic criteria, if applicable	•	If applicable, report whether to measure inequity as an outcome. [#]	4 (12)
Data sources/ measurement	8 * For each variable of interest, give sources of data and details of methods of	•	Report the method of obtaining population characteristics (e.g., age)	7 (21)
	assessment (measurement). Describe	•	If applicable, describe whether the techniques, especially those developed as diagnostic or quality of life measures	1 (3)

	comparability of assessment methods if	were validated or operate similarly across participants	
	there is more than one group	regardless of patients' background (e.g., ethnic/linguistic). ^{\$#}	
Bias	9 Describe any efforts to address potential sources of bias	Report efforts to reduce selection bias across PROGRESS- Plus	6 (18)
		• Report whether dimensions of context might influence the study (e.g., bias in response/participation)	5 (15)
Study size	10 Explain how the study size was arrived at	Report whether PROGRESS-Plus characteristics of interest were considered in determining the study size	7 (21)
Quantitative variables	11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and	• Report how decisions were made about analyses related to PROGRESS-Plus, including whether any categories were defined, and how they were decided	9 (26)
	why	• Report whether dimensions of context were collected for analysis	3 (9)
Ethical concerns	None	Report details of informed consent and ethical clearance	13 (38)
Statistical methods	12a Describe all statistical methods, including those used to control for confounding	• If PROGRESS-Plus factors used to control for confounding, describe how they were defined and rationale. #	3 (9)
		• Report whether contextual factors were used in adjustment for confounding. #	1 (3)
	12b Describe any methods used to examine subgroups and interactions	• Report details of additional analyses related to health equity if applicable. #	9 (26)
		Report whether context or systems were explored.	2 (6)
	12c Explain how missing data were addressed	• Explain whether missing data was related to individual or contextual factors associated with health inequities.	2 (6)
Results			
Participants	13a.* Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study,	-	
	13b Give reasons for non-participation at each stage	• Describe the losses and exclusions of participants across PROGRESS-Plus.	5 (15)
		Describe non-response/nonparticipation across PROGRESS-Plus.	2 (6)
	13c.* Consider use of a flow diagram	-	
Descriptive data	14a Give characteristics of study participants (e.g., demographic, clinical,	• Present characteristics across relevant PROGRESS-Plus characteristics.	11 (32)

	social) and information on exposures and		
	potential confounders		
	14b Indicate number of participants with	• Describe whether data on PROGRESS-Plus factors are	3 (9)
	missing data for each variable of interest	missing (e.g., ethnicity data in some settings has a high level of missingness.	
	14c.* Cohort study—Summaries follow-up	-	
	time (e.g., average and total amount)		
Data	15.* Cohort study—Report numbers of	-	
	outcome events or summary measures over time	6	
	Case-control study-Report numbers in		
	each exposure category, or summary		
	measures of exposure		
	Cross-sectional study—Report numbers of		
1	outcome events or summary measures		
Main result	16a Give unadjusted estimates and, if	• Report if confounders were defined for contextual or	2 (6)
	applicable, confounder-adjusted estimates	PROGRESS-Plus factors that are associated with health	- (-)
	and their precision (e.g., 95% confidence	inequities	
	interval). Make clear which confounders		
	were adjusted for and why they were		
	included		
		• Justify why certain categories of PROGRESS-Plus are not	2 (6)
		disaggregated for analysis	
	16b. Report category boundaries when	-	
	continuous variables were categorized		
	16c. If relevant, consider translating	-	
	estimates of relative risk into absolute risk		
	for a meaningful time period		
Other analysis	17 Report other analyses done (e.g.	• Report other analyses to address health equity questions, if	6 (18)
	analyses of subgroups and interactions, and	the study had objectives related to health equity. #	
	sensitivity analyses)		
Discussion			
Key results	18. Summaries key results with reference	-	
	to study objectives		
Limitations	19. Discuss limitations of the study, taking	• Report any limitations related to assessing effects on health	3 (9)
	into account sources of potential bias or	equity. ^{\$#}	
	imprecision. Discuss both direction and		
	magnitude of any potential bias		

Interpretation	20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	•	Consider importance of context in interpretation of health equity. [#]	7 (21)
Generalizability	21 Discuss the generalisability (external validity) of the study results	•	Discuss external validity to populations across relevant PROGRESS-Plus characteristics, considering issues of possible self-selection, healthy volunteer bias, losses across PROGRESS-Plus	6 (18)
		•	Consider implications of exclusion of people across PROGRESS as well as differential participation and/or loss to follow-up	3 (9)
		•	Consider context in discussion of generalizability	9 (26)
Implications for research ^{\$}	None	•	Provide implications for research, practice or policy related to health equity where relevant (e.g., types of research needed to address unanswered questions). ^{\$#}	1 (3)
Other information			.01	
Funding	22. Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	2		
Data sharing ^{\$}	None	•	Describe where the raw data across PROGRESS-plus factors could be accessed. [§]	1 (3)
studies. \$ New items suggested based	y for cases and controls in case-control studies d on resources identified in this review.		, if applicable, for exposed and unexposed groups in cohort and	

Some items are more generic for all observational studies, while some (with #) maybe more specific to observational studies related to health equity.

Highlights

- All candidate items proposed to extend STROBE (Strengthening Reporting of Observational studies in Epidemiology) for equity were supported by at least one resource.
- We identified 13 additional items related to defining health equity terms; these described the role of racism and discrimination, composition and training of the researcher(s), considering relevant factors in the study methods, and data sharing specific to and across equity factors.
- These items will be used for the consensus process to develop a research reporting guideline on health equity to extend STROBE.



Declaration of interests

□ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☑ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Vivian A Welch reports financial support was provided by Canadian Institutes of Health Research. Luis Gabriel Cuervo is an official of the Pan American Health Organization, but the views expressed in this publication are his sole responsibility and do not necessarily represent the decisions or policies of the Pan American Health Organization (PAHO/WHO).

....tt

Author statement

XW, OD, AR, LM, and VW conceptualised this review. TR conducted the literature search. XW, OD, MM, AR, JH, PD, RJD, and EG screened the references and extracted the data. XW analyzed the data and drafted the manuscript. OD, AR, EG, TR, SGN, AA, BS, BJH, CC, CSW, CF, DOL, EAO, EK, EE, HW, HE, CJP, HSW, JR, JGR, JJ, JT, JL, LM, LW, LLN, LGC, LW, MK, MTA, MKS, MJM, MN, OM, PC, PT, SF, SGN, TK, TH, TY, TP, ZB, AM and VW revised the manuscript. All authors reviewed and edited the manuscript and approved the final draft. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Jonulua